Children versus adults: pharmacokinetic and adverse-effect differences

Area of Science:

• Pharmacology
• Pediatric Adverse Drug Reactions
• Drug Metabolism

Background:

• Adverse drug reactions (ADRs) to lamotrigine (LTG) and valproate (VPA) present unique challenges in pediatric populations.
• Idiosyncratic reactions, such as rash with LTG and hepatotoxicity with VPA, exhibit age-related incidence differences.
• Understanding pharmacokinetic variations is crucial for managing pediatric ADRs.

Purpose of the Study:

• To explore age-related pharmacokinetic differences influencing adverse effects of LTG and VPA in children.
• To investigate the role of cytochrome P450 (CYP) metabolism in LTG-induced rash in pediatric patients.
• To examine risk factors for VPA-associated hepatotoxicity in young children.

Main Methods:

• Comparative analysis of LTG and VPA pharmacokinetics in children versus adults.
• Identification of LTG metabolites, including CYP-catalyzed arene oxide intermediates.
• Review of clinical data on VPA hepatotoxicity, focusing on patient demographics and co-therapies.

Main Results:

• Children exhibit increased CYP-mediated metabolism of LTG, potentially leading to higher formation of reactive metabolites and increased rash incidence.
• Higher milligram per kilogram doses of LTG in children further contribute to reactive metabolite production.
• VPA hepatotoxicity, rare but fatal, predominantly affects children under 2 with pre-existing conditions; polytherapy with enzyme inducers exacerbates risk.

Conclusions:

• Pharmacokinetic differences, particularly enhanced CYP metabolism and higher dosing in children, increase the risk of LTG-induced rash.
• Underlying metabolic disorders and polytherapy complicate the understanding of VPA-induced hepatotoxicity in pediatric patients.
• Age-specific dosing and careful monitoring are essential for mitigating LTG and VPA adverse effects in children.